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 ABSTRACT
 To assess the regulation of mammary cell activity, sur-
vival, and proliferation by prolactin (PRL), 5 Holstein 
cows in early lactation received daily i.m. injections of 
1 mg of quinagolide, a suppressor of PRL release, for 9 
wk, whereas 4 control cows received the vehicle (water) 
only. During the last week of treatment, one udder half 
was milked once a day (1×) and the other twice a day 
(2×). Mammary biopsies were harvested 1 wk before 
and 4 and 8 wk after the start of quinagolide treatment. 
The quinagolide injections reduced milk yield and re-
sulted in lower levels of κ-casein and α-lactalbumin 
mRNA in the mammary biopsies at wk 4 compared 
with the control cows. In the mammary tissue of the 
quinagolide-treated cows at wk 8 of treatment, cell pro-
liferation (as determined by proliferating cell nuclear an-
tigen labeling) was lower and apoptosis (as determined 
by the terminal deoxynucleotidyl transferase-mediated 
dUTP nick-end labeling assay) was higher than in the 
mammary tissue of the control cows. During differ-
ential milking, mammary epithelial cells (MEC) were 
extracted from the milk by centrifugation and purified 
by immunocytochemical binding to allow variations in 
the levels of mammary transcripts to be observed. After 
9 wk of treatment, levels of α-lactalbumin and κ-casein 
mRNA were lower in the MEC isolated from milk of 
the quinagolide-treated cows. This effect was associated 
with lower PRL receptor mRNA levels and a tendency 
toward lower viability in the milk-isolated MEC from 
the 2×-milked glands. The decrease from 2× milking 
to 1× milking also downregulated α-lactalbumin and 
κ-casein transcripts in the milk-isolated MEC. Viability 
was higher for the MEC collected from the 1×-milked 
udder halves compared with the 2×-milked halves. In 
conclusion, the reduction in milk yield after chronic 
administration of the PRL-release inhibitor quinagolide 
is associated with a reduction in mammary cell activ-
ity, survival, and proliferation in lactating dairy cows. 
Reduced milking frequency was also associated with a 
decrease in MEC activity. 
 Key words:   prolactin ,  proliferation ,  apoptosis ,  milk 
mammary epithelial cell 
 INTRODUCTION 
 Milk production depends on both the activity and the 
number of mammary epithelial cells (MEC). Changes 
in the number of cells in the mammary gland during 
lactation are caused by mammary cell turnover result-
ing from 2 opposing mechanisms, cell proliferation and 
cell death (mainly through apoptosis). The decline in 
milk production after the peak of lactation appears to 
be due to a gradual reduction in the number of milk-
secreting cells, given that the rate of proliferation is 
lower than the rate of apoptosis (Knight and Wilde, 
1987; Capuco et al., 2003). The mechanisms that are 
responsible for the variations in the activity and num-
ber of mammary cells during lactation are still poorly 
understood in ruminants. 
 Prolactin (PRL), whose release by pituitary lacto-
trophs is enhanced after teat stimulation at milking, 
is the hormone traditionally presumed to play a major 
role in the maintenance of lactation. In rodents and 
rabbits, the inhibition of PRL release during lacta-
tion was found to clearly inhibit lactation (Taylor and 
Peaker, 1975; Travers et al., 1996). In contrast, studies 
performed in cows and goats showed controversial re-
sults regarding the galactopoietic role of PRL in these 
species (Knight, 2000). Thus, in ruminants, the role of 
PRL during lactation had not been clear until a recent 
experiment using an efficient inhibitor of PRL release, 
the dopamine D2 receptor agonist quinagolide, showed 
that PRL potentially plays a role in the maintenance 
of lactation (Lacasse et al., 2011). However, the mecha-
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nism by which the PRL inhibitor reduces milk produc-
tion remains to be determined.
Although the in vivo evidence for a galactopoietic 
role of PRL in ruminants is scarce, PRL clearly modu-
lates the activity and number of ruminant mammary 
cells in vitro. Prolactin stimulates the synthesis of milk 
in ruminant mammary explants or cultivated MEC 
(Skarda et al., 1982; Choi et al., 1988). Prolactin also 
stimulates the proliferation of bovine MEC (Olazabal 
et al., 2000) and protects them from apoptosis (Accorsi 
et al., 2002). Despite those findings, the role of PRL 
in mammary cell activity, survival, and proliferation 
has not yet been clearly shown in vivo. Indeed, the 
administration of PRL did not modify cell turnover in 
bovines (Wall et al., 2006). Our assumption is that, in 
ruminants, supplementation of the basal level of PRL 
by exogenous administration is not able to modify 
mammary functions, whereas endogenous PRL release 
at milking modulates the activity and number of mam-
mary cells.
Reducing milking frequency from twice daily (2×) 
to once daily (1×) was shown to cause a 10 to 30% 
decrease in milk yield associated with changes in MEC 
activity (Littlejohn et al., 2010; Ben Chedly et al., 
2011). Indeed, the reductions in milk, lactose, protein, 
and fat yields caused by 1× milking are clearly asso-
ciated with a reduction in milk protein mRNA levels 
(Ben Chedly et al., 2011). The reduction in milk yield 
caused by PRL inhibition could be triggered by similar 
cellular mechanisms.
We are interested in gaining a better understand-
ing of the effect of milking-induced PRL release on 
mammary gland functions. To assess the effect of PRL, 
we inhibited its secretion with quinagolide injections. 
The purpose of this study was to evaluate whether 
PRL acted on the activity, survival, and proliferation 
of epithelial cells in the bovine mammary gland and 
whether the reduction to 1× milking triggered similar 
mechanisms.
MATERIALS AND METHODS
Animals and Experimental Procedures
All the procedures used on animals were approved 
by the animal care committee of the French Ministry 
of Agriculture in accordance with French regulations 
(Decree No. 2001-464; May 29, 2001).
The experimental design and procedures were de-
scribed by Lacasse et al. (2011). Briefly, 10 Holstein 
cows at 62 ± 4 DIM and housed at the Mejusseaume 
experimental farm of the Institut national de la recher-
che agronomique (INRA, Le Rheu, France) were milked 
twice a day for a 9-wk period that consisted of a 1-wk 
pretreatment period and 8 wk of treatment. During wk 
9 of treatment, the cows were subjected to 1 wk of dif-
ferential milking (1× milking in one udder half and 2× 
milking in the other half).
During the 9-wk treatment period, 5 of the cows 
received daily (at 1000 h) i.m. injections of 1 mg of 
quinagolide (Ferring, Wallisellen, Switzerland) diluted 
in water, and the other 5 cows received water injections 
(control). One multiparous cow was withdrawn from 
the control group for health reasons.
Mammary Biopsies
Biopsies were taken from the upper portion of the 
mammary gland 1 wk before and 4 and 8 wk after 
the start of quinagolide treatment. The first 2 mam-
mary biopsies were obtained using a 12-gauge, 10-cm, 
22-mm Bard Monopty disposable core biopsy instru-
ment (Bard, Voisins-le-Bretonneux, France), and the 
last biopsy, at 8 wk, was obtained using the 70 × 4 
mm instrument described by Farr et al. (1996). Before 
the tissue biopsies, local anesthesia was applied by s.c. 
injection of 40 mg of Xylocaine (Astra France, Rueil-
Malmaison, France). A skin incision was performed with 
a scalpel. The 22-mm core instrument was inserted 2 or 
3 times to obtain sufficient tissue, whereas the 70-mm 
instrument was inserted only once. After the tissue col-
lection using the 70-mm instrument, a 4- × 5-cm plug 
of absorbable hemostat (Surgicel, Johnson & Johnson 
Medical, Ethicon, Issy-les-Moulineaux, France) was 
inserted into the wound using a syringe (Terumo 6% 
Luer, Fisher Bioblock, Illkirch-Graffenstaden, France). 
A soft gauze pad was applied with pressure to the ud-
der to control hemorrhage. The skin incision was closed 
with a disposable skin stapler (Royal 35W, Clinique 
Vétérinaire, Saint-Grégoire, France). The cows received 
an antibiotic by means of an i.m. injection of 0.6 g of 
Excenel (Pfizer Santé Animale, Paris, France) for 3 d.
Mammary tissues obtained 1 wk before and 4 wk 
after the start of quinagolide treatment were used for 
RNA extraction only. The biopsies performed after 8 
wk were rinsed in sterile saline solution to remove all 
traces of blood and cut into 2 parts, one of which was 
immediately frozen in liquid nitrogen and stored at 
−80°C for separate RNA, DNA, and protein analyses. 
The other part was washed in PBS and fixed in 4% 
paraformaldehyde for immunohistochemical analysis. 
The fixed tissue was cryoprotected by incubation for 
48 h in a 40% sucrose solution and then coated with 
Tissue-Tek O.C.T. compound (Sakura Finetek Europe, 
LaboNord, Templemars, France), frozen in a cooled 
bath of isopenthane, and stored at −80°C until use.
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Isolation of MEC from Milk
Milk epithelial cells were prepared once during the 
differential milking period. Milk from the morning 
milking was collected separately for each udder half 
to prepare total milk cells. Then, epithelial cells were 
isolated from total milk cells as described previously 
by Boutinaud et al. (2008), with some modifications. 
Briefly, 2.3 kg of fresh milk was defatted by 15 min 
of centrifugation at 1,500 × g at 4°C in several 230-
mL tubes (VWR International, Fontenay-sous-Bois, 
France). The skim milk was removed, and the remaining 
total cell pellet was resuspended and pooled in 150 mL 
of PBS (Gibco, Invitrogen, Cergy Pontoise, France). 
The cell suspension was washed twice in PBS, filtered, 
and finally resuspended in 2 mL of PBS containing 1% 
BSA (Sigma Aldrich, Lyons, France). This cell suspen-
sion was analyzed for cell count and viability deter-
minations using Kova slides (CLM, Nemours, France) 
under light microscopy and a Vi-CELL XR analyzer 
(Beckman Coulter, Roissy, France). The 1% BSA-PBS 
cell suspension was used for MEC isolation with an 
immunomagnetic separation technique. Briefly, Dy-
nabeads (Pan Mouse IgG, Dynal Biotech, Invitrogen) 
were first coated with a primary mouse monoclonal 
antibody directed against cytokeratin 8 antibody (clone 
K8.13, Sigma Aldrich). Each cell sample was incubated 
with the bead and antibody mix. After 1 h of incuba-
tion, the samples were placed in a magnetic particle 
concentrator (MPC-S, Dynal Biotech, Invitrogen), and 
the supernatant containing the nonselected cells was 
removed. The isolated MEC were resuspended in 1 mL 
of 1% BSA-PBS. This cell suspension was analyzed for 
cell count and viability determinations. The MEC were 
pelleted by centrifugation (5 min, 4°C, 5,000 × g), and 1 
mL of Trizol (Invitrogen Life Technologies) was added. 
The cell samples were mixed and stored at −80°C until 
total RNA extraction was performed.
Real-Time Reverse-Transcription PCR
Extraction of total RNA from the mammary tissue 
samples and milk-isolated MEC samples was performed 
as previously reported (Boutinaud et al., 2008). The 
concentration of total RNA was analyzed by spectro-
photometry, and the integrity of total RNA given by 
the RNA integrity number was checked using a 2100 
Bioanalyzer (Agilent Technologies, Massy, France). 
Treatment of total RNA samples (from 500 ng for both 
types of samples) for reverse transcription and real-
time PCR analysis using SYBR Green PCR Master 
Mix (Applied Biosystems, Foster City, CA) was carried 
out as described previously (Boutinaud et al., 2008). 
The primers used for real-time PCR for proliferating 
cell nuclear antigen (PCNA), (forward 5 -TTTG-
CACGTATATGCCGAGATC-3 ; reverse 5 -TATG-
GCAACAGCTTCCTCCTC-3 ), for PRL receptor 
(PRLR) long isoform (forward 5 -TGCTGTCATCT-
GTTTGATTATGGTC-3 ; reverse 5 -TTGCTCCGT-
GTGTTCTTTGG-3 ), and for PRLR short isoform 
(forward 5 -GCTATAGCATGGTGACCTGCATC-3 ; 
reverse 5 -CGGACTTGCCCTCCTATTAAAAC-3 ) 
were designed using the Primer Express 1.0 software 
program (Applied Biosystems) and synthesized by 
MWG Biotech (Roissy, France). The other primers 
used were described in previous studies (Boutinaud 
et al., 2008; Ben Chedly et al., 2009). For each gene 
analyzed, a standard curve made with serial dilutions 
of one sample of mammary gland reverse transcript was 
used to quantify the mRNA levels. The mRNA levels 
of the studied genes were expressed relative to a house-
keeping gene. The genes cyclophilin, R18S, GAPDH, 
and ribosomal protein large P0 (RPLP0) were evalu-
ated as potential housekeeping genes. The BestKeeper 
(Pfaffl et al., 2004) and NormFinder (Andersen et al., 
2004) programs were used to assess the variability 
of the candidate housekeeping genes. These analyses 
indicated that RPLP0 was the most stable housekeep-
ing gene in this experiment. For each gene, the mRNA 
level was expressed as a semi-absolute mRNA molecule 
number (Boutinaud et al., 2004). For each target gene, 
the results were expressed as a ratio using the selected 
housekeeping gene, namely RPLP0.
Protein Extraction and Western Blot Analysis
Total and nuclear proteins were extracted from fro-
zen mammary gland tissues after 8 wk of quinagolide 
treatment. Total proteins were extracted using T-PER 
Tissue Protein Extraction Reagent (Pierce, Perbio 
Science, Brebières, France). Frozen mammary tissue 
samples (15 mg) were homogenized in 40 volumes (wt/
vol) of T-PER lysis buffer using an Ultra-Turrax ho-
mogenizer (Fisher Bioblock) as recommended by the 
manufacturer. After centrifugation at 10,000 × g for 
5 min at 4°C, the supernatant containing the total 
protein extracts was recovered and quickly frozen. To 
obtain nuclear protein extracts, frozen mammary tis-
sue samples (20 mg) were homogenized in 5 volumes 
(wt/vol) of Cytoplasmic Extraction Reagent I from the 
NE-PER Nuclear and Cytoplasmic Extraction Reagent 
Kit (Pierce) using an Ultra-Turrax homogenizer. After 
the tubes were vortexed vigorously, the lysates were 
incubated on ice for 10 min. Cytoplasmic Extraction 
Reagent II (5%) was added to the lysates to disrupt the 
cell membranes and release the cytoplasmic contents. 
The intact nuclei were recovered from the cytoplasmic 
extract by centrifugation at 13,000 × g for 5 min at 
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4°C. The pellet was resuspended in 100 μL of ice-cold 
Nuclear Extraction Reagent. The tubes were vortexed 
and incubated on ice for 40 min as recommended by 
the manufacturer. The nuclear preparation was cleared 
by centrifugation at 13,000 × g for 10 min. The su-
pernatant containing the nuclear extract was quickly 
frozen. The protein concentration was determined by 
the Lowry method using the DC Protein Assay Kit 
(Pierce) as described by the manufacturer. Then, the 
protein lysates were combined with sample buffer con-
taining 50 mM Tris-HCl, pH 6.8 (Bio-Rad, Marnes-
la-Coquette, France), 2% SDS, 0.1% bromophenol 
blue (Sigma Aldrich), 20% glycerol (Fisher Scientific 
Bioblock), and 5% β-mercaptoethanol (Sigma Aldrich), 
boiled for 5 min at 95°C, and resolved by SDS-PAGE. 
Proteins (30 μg per lane) and prestained molecular 
mass standards (Fermentas, Saint-Rémy-lès-Chevreuse, 
France) were separated on 10% SDS-polyacrylamide 
gels, electro-transferred overnight to polyvinylidene 
difluoride membranes (Amersham Biosciences, Orsay, 
France), and incubated with blocking solution [5% dry 
skim milk dissolved in Tris-buffered saline–Tween 20 
(Bio-Rad), 50 mM Tris-HCl pH 8.6 (Bio-Rad), 150 
mM NaCl (Sigma Aldrich), and 0.1% Tween (Sigma 
Aldrich)] for 30 min. The membranes were then incu-
bated overnight at 4°C with the appropriate dilution of 
the following primary antibodies: a mouse monoclonal 
anti-PCNA (clone PC10, DakoCytomation, Glostrup, 
Denmark; diluted 1:5,000) and a mouse monoclonal 
anti-β-actin (A5441, Sigma Aldrich; diluted 1:5,000). 
Then, the membranes were washed with Tris-buffered 
saline–Tween 20 before incubation with horseradish 
peroxidase-conjugated anti-mouse secondary anti-
bodies (31450, Pierce) for 1 h at room temperature. 
Peroxidase activity was detected using an enhanced 
chemiluminescence detection system (ECL System, 
Amersham Biosciences). The membranes were exposed 
to Curix Ortho HT-G films (Agfa, Mortsel, Belgium), 
which were then digitized at 16-bit/600-dpi resolution 
using a Canoscan D1250U2 scanner (Canon, Courbev-
oie, France). The images were saved as TIFF files and 
calibrated to an optical density scale. The integrated 
optical density of the bands was quantified using the 
ImageJ software program (Wayne Rasband, National 
Institutes of Health, Bethesda, MD). Each sample was 
normalized according to β-actin content.
Immunohistochemistry for Proliferation
and Apoptosis Assays in Mammary Tissue Sections
Proliferating cells were identified in mammary tissue 
after 8 wk of quinagolide treatment as cells express-
ing the PCNA antigen, as previously reported (Colitti 
et al., 2005). Cryosections measuring 7 μm thick 
were mounted onto Superfrost/Plus slides (Prolabo, 
Bondoufle, France). Mammary gland sections were 
quenched in PBS with 3% hydrogen peroxide and 10% 
methanol for 30 min. After several washes with PBS, 
the sections were permeabilized with 1% SDS-PBS for 
5 min, washed 3 times in PBS, and pre-incubated in 
1% BSA-PBS for 1 h at room temperature. The tis-
sues were then incubated in the presence or absence of 
a primary antibody (M0879, monoclonal mouse clone 
PC10, DakoCytomation; diluted 1:200) in the same 
buffer overnight at 4°C. After washes with 1% BSA/
PBS, the samples were incubated with 1:200-diluted 
second antibody (F5387, goat anti-mouse fluorescein 
isothiocyanate–conjugated antibody, Sigma Aldrich) 
for 1 h at room temperature. Subsequently, the mam-
mary gland sections were counterstained for 3 min 
with 4 ,6-diamidino-2-phenylindole (DAPI, D9542, 
Sigma Aldrich) at 33 μg/mL and then for 3 min with 
propidium iodide (P4864, Sigma Aldrich) at 333 μg/
mL.
The determination of apoptosis in the mammary gland 
biopsies was based on DNA fragmentation detection 
using terminal deoxynucleotidyl transferase-mediated 
dUTP nick-end labeling (TUNEL) staining. Cryosec-
tions measuring 7 μm thick that had been mounted 
onto slides treated with 3-aminopropyltriethoxysilane 
(Sigma Aldrich) were thawed and incubated for 30 min 
at 70°C in a solution of 10 mM citrate sodium (Sigma 
Aldrich) and 0.1% Triton (Fisher Scientific Bioblock), 
washed in PBS, and incubated for 30 min at 37°C in 
200 ng/μL proteinase K solution (Promega, Madison, 
WI). The tissue sections were incubated with reagents 
from the DeadEnd Fluorometric TUNEL System (Pro-
mega) according to the manufacturer’s instructions. 
After the TUNEL reaction was stopped, the mammary 
gland sections were counterstained by incubation for 3 
min with DAPI (Sigma Aldrich) at a concentration of 
333 μg/mL.
After washing, the slides were mounted with Vecta-
shield (Valbiotech, Paris, France) and examined under 
fluorescence microscopy using an Eclipse E400 micro-
scope (Nikon France, Le Pallet, France). The pictures 
were captured by a DXM 1200 digital still camera 
(Nikon) and analyzed with the ImageJ software. Eight 
microscopic fields (magnification: 200×; area: 0.14 mm2 
per microscopic field) were examined for each tissue 
sample. The percentage of apoptosis or proliferation in 
the mammary gland was determined as a ratio of the 
TUNEL-labeled or PCNA-positive cells to the DAPI-
counterstained nuclei. Epithelial cells positive for PCNA 
were determined with propidium iodide staining, which 
draws the outlines of the acini. For each acinus, the 
ImageJ software was used to count the number of cells 
and determine alveolar size.
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DNA Quantification of Mammary Tissue
Mammary tissue samples (50 mg) were first weighed 
and homogenized in 2.5 mL sodium phosphate extrac-
tion buffer (0.05 M Na2HPO4, 0.05 M NaH2PO4, 2 mM 
EDTA, and 2 M NaCl, pH 7.4, Sigma Aldrich). Then, 
the mixture was ground using an Ultra-Turrax homog-
enizer, sonicated for 1 min, and centrifuged at 4,000 × 
g for 1 h. The supernatant was transferred to another 
tube, and the pellet was resuspended in 2.5 mL of the 
extraction buffer. Subsequently, the pellet was sub-
jected to 3 successive extraction steps, namely grind-
ing, sonication, and centrifugation, as described above. 
At the end of each centrifugation, the supernatant was 
recovered and added to the first. The DNA concen-
tration in the mixture was determined by fluorescence 
using Hoechst 33258 dye (Sigma Aldrich). Aliquots of 
the DNA mixture were mixed with sodium phosphate 
buffer stained with Hoechst dye to a final dye concen-
tration of 1 μg/mL. The reactions were performed in a 
200-μL final volume in a black 96-well microplate. Se-
rial dilutions of calf thymus DNA (Sigma Aldrich) were 
used to generate a standard curve. The plates were di-
rectly read with the Mithras LB940 fluorescence plate 
reader (Berthold Technologies, Thoiry, France) at 355 
nm excitation and 460 nm emission wavelengths. The 
DNA concentrations in the mammary tissue samples 
were calculated by extrapolation from the standard 
curve and correction for aliquot volume.
Statistical Analyses
The statistical analyses of the real-time PCR results 
were performed on the basis of semi-absolute data 
normalized individually by RPLP0 multiplied by 104 
and log10-transformed. The PCR data for the biopsy 
samples were analyzed by ANOVA using the MIXED 
procedure of SAS (SAS Institute Inc., Cary, NC) with 
a REPEATED statement. Time was used as a repeated 
effect, and cow(treatment) was used as the subject. 
The data for cell proliferation and apoptosis, protein 
and DNA contents, and alveolar characteristics in 
the mammary gland were analyzed by ANOVA using 
the MIXED procedure of SAS. The proliferation rate 
obtained in the entire mammary tissue was compared 
with that in the MEC by testing the H0 hypothesis that 
the rates did not differ using a paired Student’s t-test. 
The data for the PCR results in the milk-isolated MEC 
were analyzed by least squares ANOVA using the GLM 
procedures in the epsilon Windows software (L. Delaby, 
UMR1080, Production du lait, INRA, France). The 
split-plot linear model was used to test the effects of 
milking frequency, quinagolide treatment, quinagolide 
treatment within the cow, and the interaction between 
milking frequency and quinagolide treatment. Differ-
ences were considered statistically significant when P 
< 0.05.
RESULTS
Effects of Quinagolide Treatment and Differential 
Milking on Milk Yield and Composition
The results for milk yield and composition were re-
ported previously (Lacasse et al., 2011). Briefly, daily 
injections of quinagolide reduced milking-induced PRL 
release (P < 0.05) but not basal PRL concentration. 
Quinagolide induced a faster decline in milk production 
(P < 0.05) compared with the control treatment. The 
milk production of the quinagolide-treated cows was 
5.3 kg/d less than that of the control cows during the 
last 4 wk of treatment. Milk fat, protein, and casein 
contents were not affected by the treatment, whereas 
lactose content was reduced (P < 0.05) in the quina-
golide-treated cows in wk 5, 6, and 7. Milk fat, lactose, 
and protein yields were lower in the quinagolide-treated 
animals than in the controls (P < 0.05).
Differential milking resulted in modifications in milk 
yield and composition. Reductions in milk produc-
tion and fat and protein yields were observed in the 
1×-milked udder halves (P < 0.001) compared with the 
2×-milked halves. The inhibitory effect of quinagolide 
was maintained in the 2×-milked udder halves (P < 
0.05) but was lost in the 1×-milked halves (P > 0.15).
Transcript Levels in the Mammary Gland
Before the start of quinagolide treatment, the levels 
of α-LA and κ-CN mRNA were similar between the 2 
groups of animals (Table 1). After 4 wk of treatment, 
quinagolide injections induced reductions in the α-LA 
and κ-CN mRNA levels (−73%, P = 0.06 and −75%, P 
= 0.05, respectively). The mRNA levels of these genes 
were not different after 8 wk of treatment. Quinagolide 
treatment had no effect on glucose transporter 1 
(GLUT1), caspase 3, bax, or bcl 2 mRNA levels in the 
mammary gland (Table 1). At no time did quinagolide 
treatment affect PRLR long and short isoform mRNA 
levels (Table 1) in the mammary tissue.
Number and Transcript Levels of Milk-Isolated MEC
Mammary epithelial cells were collected from the 
1×- and 2×-milked udder halves during wk 9 of treat-
ment. The number of milk-isolated MEC averaged 14.7 
× 103 ± 4.1 × 103 cells/mL milk, representing 9.3 ± 
1.9% of the total cells recovered in the milk. The total 
number of cells was not affected by either quinagolide 
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treatment or milking frequency. Quinagolide treatment 
had no effect on the loss MEC in milk per day, whereas 
this number tended to be lower in the 1×-milked udder 
halves than in the 2×-milked halves (Table 2).
The viability of isolated MEC was not affected by 
quinagolide but was higher for the cells collected from 
the 1×-milked udder halves than for those from the 
2×-milked halves (P = 0.03; Table 2). Quinagolide did 
not affect MEC viability (P = 0.14; Table 2). When 
the 2×-milked halves were considered alone, however, 
quinagolide treatment had a tendency to reduce milk-
isolated MEC viability compared with the control 
treatment (P = 0.08).
Total RNA recovered from the milk-isolated MEC 
averaged 34.5 ± 9.1 μg. The quality and quantity of 
total RNA for the milk-isolated MEC samples were 
good except for one sample that was removed from the 
trial (RNA integrity number <4). During the differen-
tial milking, the mRNA levels of α-LA and κ-CN were 
lower in the milk-isolated MEC from both the 1×- and 
2×-milked udder halves in the quinagolide-treated cows 
compared with the control cows (P = 0.001 for both 
genes; Table 2). Similarly, quinagolide treatment was 
associated with lower levels of the PRLR long isoform 
transcript (P = 0.02). This effect was significant in the 
MEC from the 2×-milked udder halves (P = 0.04) but 
not in the MEC from the 1×-milked halves (P = 0.12). 
In contrast, the levels of the PRLR short isoform tran-
script were not affected by quinagolide treatment (P = 
0.13). As in the mammary gland, the mRNA levels of 
Table 1. Effect of the injection of water (control; n = 4) or quinagolide (Quin; 1 mg/d; n = 5) on mRNA levels in mammary tissue in wk −1, 
4, and 8 relative to the start of treatment 
Item1
Week −1 Week 4 Week 8
Control Quin P-value2 Control Quin P-value2 Control Quin P-value2
α-Lactalbumin 27,000 21,900 0.76 53,700 13,600 0.06 55,500 34,000 0.49
κ-Casein 29,900 35,800 0.77 64,400 17,100 0.05 75,700 66,200 0.83
PRLR long isoform 3.2 5.3 0.43 3.8 1.7 0.20 3.7 7.3 0.28
PRLR short isoform 30.8 33.1 0.84 28.1 24.8 0.74 33.7 46.1 0.41
GLUT1 2.0 1.9 0.77 1.6 1.1 0.18 2.5 2.8 0.63
PCNA 6.9 7.7 0.63 6.5 7.8 0.41 7.7 6.7 0.48
Caspase 3 0.6 1.1 ≤0.01 0.9 0.7 0.18 1.5 1.3 0.52
Bax 0.38 0.19 0.12 0.14 0.23 0.28 0.26 0.24 0.81
Bcl 2 0.36 0.51 0.32 0.36 0.44 0.55 0.38 0.29 0.46
Bax/bcl 2 1.10 0.42 ≤0.01 0.47 0.54 0.75 0.78 0.86 0.70
RPLP0 392,000 377,000 0.87 382,000 302,000 0.33 395,000 556,000 0.17
1PRLR = prolactin receptor; GLUT1 = glucose transporter 1; PCNA = proliferating cell nuclear antigen; RPLR0 = ribosomal protein large P0.
2Statistical analyses were performed on the semi-absolute mRNA molecule number relative to RPLP0 multiplied by 104 and log10-transformed. 
Data presented are retransformed into the semi-absolute mRNA level ratio multiplied by 100, except for RPLP0, which is expressed as a semi-
absolute number of molecules.
Table 2. Effect of injection of water (control; n = 4) or quinagolide (Quin; 1 mg/d; n = 5) and differential milking (1×, once-daily milking of 
one udder half; 2×, twice-daily milking of the other udder half) on mammary epithelial cells (MEC) recovered in milk and on mRNA levels in 
milk-isolated MEC during wk 9 of quinagolide treatment 
Item1
2× 1× P-value2
Control Quin Control Quin MF Quin MF × Quin
MEC/mL of milk 14,166 17,799 14,166 12,551 0.52 0.80 0.52
Milk MEC viability (%) 77.5ab 51.3a 91.7b 87.2b 0.03 0.14 0.28
Loss of MEC in the milk (106 cells/d) 309 288 172 131 0.06 0.66 0.89
α-Lactalbumin 1,313a 156b 316b 53c ≤0.01 ≤0.01 0.57
κ-Casein 365a 41b 143a 20b 0.04 ≤0.01 0.75
PRLR long isoform 0.39a 0.06b 0.16ab 0.05b 0.31 0.02 0.51
PRLR short isoform 0.13 0.05 0.09 0.02 0.38 0.13 0.73
GLUT1 1.65 1.15 1.87 1.77 0.38 0.49 0.61
Bax 1.75 2.23 2.60 2.75 0.28 0.58 0.71
Bcl 2 2.44 2.69 2.53 2.06 0.49 0.74 0.38
Bax/bcl 2 0.71 0.60 0.92 1.12 0.12 0.93 0.51
RPLP0 291,000 300,000 367,000 330,000 0.31 0.80 0.67
a–cFor significant difference according to MF × Quin treatments.
1PRLR = prolactin receptor; GLUT1 = glucose transporter 1; RPLR0 = ribosomal protein large P0.
2Statistical analyses were performed on the semi-absolute mRNA molecule number relative to RPLP0 multiplied by 105 and log10-transformed. 
Data presented here are retransformed into the semi-absolute mRNA level ratio multiplied by 100, except for RPLP0, which is expressed as a 
semi-absolute number of molecules. Effects: MF = milking frequency; Quin = quinagolide.
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GLUT1, caspase 3, bax, and bcl 2 were not affected by 
quinagolide treatment in the milk-isolated MEC.
As with quinagolide treatment, milking frequency 
induced variations in milk protein mRNA levels in the 
milk-isolated MEC (Table 2). Transcripts of α-LA and 
κ-CN were downregulated by 1× milking compared 
with 2× milking (P ≤ 0.01 and P = 0.04 for α-LA 
and κ-CN, respectively). The mRNA levels of the other 
studied genes did not vary with milking frequency in 
the milk-purified MEC.
PCNA Protein and mRNA Expression  
and Proliferation Rate in the Mammary Gland
Analysis by Western blotting of PCNA protein levels 
in the mammary gland tissue collected in wk 8 revealed 
1 PCNA band of 36 kDa expressed in the total and 
nuclear protein extracts (Figure 1). Relative PCNA 
protein levels were lower in the total and nuclear protein 
extracts from the quinagolide-treated cows compared 
with the controls (P = 0.01 and P = 0.03, respectively). 
In contrast, PCNA mRNA levels analyzed by real-time 
reverse transcription PCR were not affected by quina-
golide treatment (Table 2). The immunohistochemistry 
analysis showed that PCNA labeling was principally 
localized in the nuclei. The counting of PCNA-positive 
cells indicated that the percentage of proliferation in the 
mammary gland was lower in the quinagolide-treated 
cows than in the controls (−50%, P = 0.02; Figure 2). 
The reduction in the percentage of PCNA-positive cells 
averaged −57% (P = 0.01) when only the MEC were 
considered. Interestingly, the proliferation rate tended 
to be higher in the MEC than in the entire mammary 
gland of both groups of animals (P = 0.08).
Apoptosis, Alveolar Structure, and DNA 
Concentration in the Mammary Gland
In the mammary biopsies collected after 8 wk of 
treatment, the level of apoptosis determined using the 
TUNEL assay was 3 times higher in the quinagolide-
treated cows than in the controls (P ≤ 0.01; Figure 2).
Quinagolide treatment had no effect on the size of 
the alveoli, which averaged 7,200 ± 1,360 and 7,010 
± 600 μm2 (P = 0.90) for the controls and the quina-
golide-treated cows, respectively. Similarly, the number 
of cells per alveolus and the number of alveoli per mi-
croscopic field did not vary with quinagolide treatment, 
averaging 40.5 ± 2.3 and 45.6 ± 8.3 (P = 0.61) and 
6.2 ± 0.6 and 7.0 ± 0.9 (P = 0.545) for the controls 
and the quinagolide-treated cows, respectively. More-
over, mammary DNA concentration did not vary with 
quinagolide treatment, averaging 1.31 ± 0.15 and 1.06 
± 0.70 mg/g of tissue (P = 0.32) for the controls and 
the quinagolide-treated cows, respectively.
DISCUSSION
This experiment studied the mechanisms by which 
quinagolide treatment reduces milk production in dairy 
cows. The decrease in milk yield induced by quinagolide 
treatment was accompanied by a decrease in α-LA and 
κ-CN mRNA levels in the mammary biopsies after 4 
wk of treatment. The effects of quinagolide on milk 
protein transcripts may be responsible for the reduced 
synthesis of milk protein and lactose. Incidentally, pro-
tein and lactose yields were lower in the quinagolide-
treated cows. The effect of quinagolide treatment on 
lactose secretion via the downregulation of the α-LA 
gene, which encodes the coenzyme of lactose synthase, 
could explain, in part, the lower milk production with 
quinagolide, given that lactose is the major osmotic 
agent in milk and therefore a regulator of milk vol-
ume. The downregulation of milk protein transcripts 
is a good indication that mammary cell activity was 
decreased by quinagolide.
The effect of quinagolide on milk protein transcripts 
is probably due to the inhibition of the milking-induced 
PRL release (Lacasse et al., 2011). Previous studies 
reported that PRL stimulates milk protein expression 
in bovine MEC (Choi et al., 1988) and that PRL in-
jections enhance α-LA mRNA expression in the mam-
mary gland of dairy cows in early lactation (Wall et al., 
2006). It is well established that the peak of PRL at 
parturition is necessary for the initiation of lactation. 
Suppression of the PRL surge at parturition inhibits 
mammary cell differentiation and lactogenesis (Akers 
et al., 1981a,b). Therefore, the milking-induced PRL 
release may help maintain the differentiation state of 
mammary cells during lactation.
Although the effect of quinagolide on milk produc-
tion was still present, the effect on milk protein mRNA 
in the mammary tissue was no longer significant after 8 
wk of treatment. Conversely, lower levels of α-LA and 
κ-CN mRNA were still observed in the milk-isolated 
MEC from the quinagolide-treated cows compared with 
the controls after 9 wk of treatment. In contrast to 
milk-isolated MEC, the mammary tissue contains other 
types of cells (myoepithelial cells, endothelial cells, adi-
pocytes, and fibroblasts), and the extraction of RNA 
from the mammary tissue may dilute the mammary 
transcripts of interest among transcripts from other 
types of cells. Thus, the purification of MEC from milk 
could constitute a more accurate method than the col-
lection of mammary tissue for observing small varia-
tions in transcript levels. Thus, the lack of significant 
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effect of the PRL inhibitor on milk protein mRNA 
levels after 8 wk of treatment could be attributed to 
the difficulty inherent in analyzing mRNA variations in 
a complex tissue.
Because glucose, the major precursor for lactose syn-
thesis, is actively transported into the mammary cells, 
it is possible that reduced expression of the main mam-
mary glucose transporter, GLUT1, is involved in the 
reduction of lactose synthesis. In rats, PRL deprivation 
induced a 40% decrease in the GLUT1 protein level in 
the mammary gland plasma membrane, whereas the 
mRNA level was not affected (Fawcett et al., 1992). 
Although quinagolide treatment decreased lactose 
yield and content, it had no effect on GLUT1 mRNA 
expression in either mammary tissue or milk-purified 
epithelial cells. Our results suggest that the regulation 
of lactose synthesis by PRL does not involve the tran-
scriptional regulation of GLUT1.
The second mechanism examined to explain the 
effect of quinagolide treatment on milk production 
was the evolution of cell turnover in the mammary 
gland. The PCNA level is an indicator of the rate of 
cell proliferation. Quinagolide treatment reduced the 
amount of PCNA protein, suggesting a lower rate of 
cell proliferation in the mammary gland. This result 
is in accordance with the proliferative effect of PRL 
Figure 1. Western blot analyses of proliferating cell nuclear antigen (PCNA) and β-actin in total (panel A) and nuclear (panel B) protein 
extracts from the mammary gland of cows treated (n = 5) or not (n = 4) with quinagolide for 8 wk. The integrated optical density of bands was 
quantified using the ImageJ software program (National Institutes for Health, Bethesda, MD) and normalized to β-actin. The bars represent the 
mean ± SEM for each type of protein extract for the control cows and the quinagolide-treated cows. *P < 0.03. 
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observed in cultivated bovine MEC (Olazabal et al., 
2000). However, this observation is not in line with the 
findings of Wall et al. (2006), who reported that in 
vivo injections of exogenous PRL failed to stimulate 
cell proliferation in the mammary gland in lactating 
dairy cows. Exogenous PRL may not affect mammary 
cell proliferation due to the saturation of PRLR, as 
suggested by Plaut et al. (1987). In contrast with that 
last study, the present study found that quinagolide 
treatment reduced endogenous PRL, suggesting that 
endogenous milking-induced PRL release is important 
for MEC proliferation during lactation.
The antiproliferative effect of quinagolide has been 
confirmed by the immunohistological detection of 
PCNA-positive nuclei. However, the percentage of 
positive cells was higher than expected. Proliferating 
cell nuclear antigen is an auxiliary protein for DNA 
polymerase γ that has a long half-life, leading to per-
sistence of staining even in cells that have recently left 
proliferative status (Yu and Filipe, 1993). Given that 
the overestimation of the proliferation rate is the same 
for all samples, however, we believe that this staining 
has biological significance.
In this experiment, the number of cells labeled by 
the TUNEL assay suggests that quinagolide treatment 
caused a higher level of apoptosis in the mammary 
gland. In agreement, DNA laddering, a marker of cell 
apoptosis, was observed in bovine mammary explants 
cultured in the absence of PRL (Accorsi et al., 2002). 
Our result is also in accordance with a study performed 
in rats showing that injections of exogenous PRL in 
animals deficient in growth hormone and PRL inhib-
ited the appearance of DNA laddering in the mammary 
gland (Travers et al., 1996). Nevertheless, the apoptotic 
effect of quinagolide was not accompanied by modifica-
tions of transcripts involved in cell death, of alveolar 
structures in the mammary tissue, or of matrix metal-
loproteinase activities (Lacasse et al., 2011), suggesting 
that remodeling of mammary tissue did not occur. The 
microscopic observations and DNA concentrations are 
probably not sensitive enough to observe variations in 
the number of cells in the mammary gland. Rather than 
acting on the number of cells in the alveolus and DNA 
concentration, PRL could increase the total number of 
alveoli, the total amount of DNA, and the total weight 
of mammary gland as was demonstrated for growth 
hormone action in the mammary gland (Baldi et al., 
2002). A better indicator would have been the weight 
of the mammary gland. Moreover, although the loss 
of MEC in milk was not affected by it, quinagolide 
treatment tended to reduce the viability of the MEC 
collected. Our study provides further evidence that 
milking-induced PRL release acts as a survival factor 
for MEC.
Similar to quinagolide treatment, the reduction of 
milking frequency from 2× to 1× induced a significant 
decrease in α-LA and κ-CN mRNA levels. The down-
regulation of milk protein gene expression was already 
shown in MEC during 1× milking in cows (Boutinaud 
et al., 2008; Littlejohn et al., 2010) and goats (Ben 
Chedly et al., 2011). Similarly, a trend toward higher 
levels of α-LA mRNA was reported when milking fre-
Figure 2. Proliferation (A) and apoptosis (B) in the mammary 
tissue of control cows (n = 4) and quinagolide-treated cows (n = 
5) for 8 wk. The mammary gland sections were first incubated with 
mouse anti–proliferating cell nuclear antigen antibody and a secondary 
fluorescein isothiocyanate–conjugated anti-goat antibody and stained 
with propidium iodide to draw the outline of the epithelium and with 
4 ,6-diamidino-2-phenylindole to counterstain the nuclei (panel A). 
The mammary gland sections were labeled by the terminal deoxy-
nucleotidyl transferase-mediated dUTP nick-end labeling assay and 
stained with 4 ,6-diamidino-2-phenylindole to counterstain the nuclei 
(panel B). *P < 0.05; **P ≤ 0.01.
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quency was increased from 2 to 4 times a day (Wall et 
al., 2006). The absence of an effect of milk frequency on 
GLUT1 mRNA is in accordance with previous results 
in cows (Boutinaud et al., 2008; Ben Chedly et al., 
2011). As reported for goats (Ben Chedly et al., 2011), 
the effect of milking frequency on GLUT1 mRNA 
might appear after more than 7 d of 1× milking. The 
effect of 1× milking on the regulation of milk protein 
mRNA expression is not the consequence of a reduced 
milking-induced PRL release, given that the 2 milking 
frequencies were performed on the same animal. The 
effect of milking frequency in our study is due to a 
local effect only. This local effect could be the conse-
quence of a chemical agent, the feedback inhibitor of 
lactation, a physical effect due to milk accumulation, 
or some combination thereof (Knight et al., 1998). Such 
local effects were found to be responsible for modifica-
tions in tight junction opening and increased matrix 
metalloproteinase activities during 1× milking; those 
modifications had not been observed with quinagolide 
treatment (Lacasse et al., 2011). Thus, the effect of 
1× milking acts partly through mechanisms similar to 
those involved in quinagolide treatment, namely the 
decrease in MEC activity.
The effect of milking frequency could be driven by 
differing PRL sensitivity indicated by changes in PRLR 
gene expression. The PRLR is expressed as short and 
long isoforms (Binart et al., 2010), which are differen-
tially expressed or regulated during the estrous cycle 
and pregnancy (Buck et al., 1992), suggesting that the 
isoforms may initiate distinct signaling pathways and 
then mediate different biological effects. The PRLR 
long isoform is involved in milk protein gene expres-
sion (Lesueur et al., 1991), whereas the short isoform 
is shown to transmit only a mitogenic signal (Das and 
Vonderhaar, 1995) and could also act as a negative 
regulator (Berlanga et al., 1997; Perrot-Applanat et 
al., 1997). Controversial results about the effects of 
milking frequency and suckling on PRLR mRNA were 
reported: PRLR mRNA was found to increase during 
thrice-daily milking compared with 1× milking or with 
more frequent suckling in the mammary tissue of cows 
and rats (Kim et al., 1997; Bernier-Dodier et al., 2010). 
In our study, however, neither the short nor the long 
isoform mRNA levels were affected during 1× milking, 
as was also observed with milking performed 4 times 
a day (Wall et al., 2006). As suggested by Wall et al. 
(2006), the effect of milking frequency on PRLR gene 
expression is probably acute and could depend on the 
sampling scheme.
An unexpected result in the present study was the 
lower level of PRLR mRNA in the milk-isolated MEC 
from the quinagolide-treated cows, although this result 
was not observed in the mammary biopsy. This result 
is in disagreement with the inverse relationship between 
circulating PRL and the expression of PRLR mRNA in 
the mammary gland of dry cows exposed to different 
photoperiods (Auchtung et al., 2005). This discrepancy 
may result from the difference between the lactating 
stage and the dry stage in cows. The effect of quina-
golide on PRLR may result from a lower differentiation 
status of epithelial cells in the mammary gland that 
are less exposed to PRL. This effect could reinforce the 
effect of PRL deprivation and explain a portion of the 
decrease in cell activity and the downregulation of milk 
protein transcripts in the quinagolide-treated cows. The 
relationship between PRLR expression in the MEC and 
PRL concentration during lactation should be further 
studied.
CONCLUSIONS
In this study, we have shown that the PRL-release 
inhibitor quinagolide acts through the regulation of 
MEC milk protein transcription and MEC survival and 
proliferation in lactating dairy cows. The regulation of 
milk protein transcription is also involved in short-term 
milking frequency changes. This study suggests that 
PRL release at milking is crucial for the maintenance 
of MEC in a differentiated status in the mammary 
gland of dairy cows. The specificity of quinagolide ac-
tions via PRL inhibition release should be evaluated by 
testing whether PRL injections in quinagolide-treated 
cows are able to restore the mammary functions. To 
confirm these results, some other dopamine agonists 
known to have strong inhibition effects on PRL release, 
such as metergoline or cabergoline, could be tested in 
the future.
ACKNOWLEDGMENTS
The authors thank P. Lamberton and his team at 
the Mejusseaume farm (UMR1080, Production du lait, 
INRA, Le Rheu, France) for taking care of the cows 
and assisting with blood sampling and injections. We 
are also grateful to S. Wiart-Letort and S. Marion 
(UMR1080, Production du lait, INRA, Saint-Gilles, 
France) for their technical assistance. This research was 
financially supported by INRA.
REFERENCES
Accorsi, P. A., B. Pacioni, C. Pezzi, M. Forni, D. J. Flint, and E. 
Seren. 2002. Role of prolactin, growth hormone and insulin-like 
growth factor 1 in mammary gland involution in the dairy cow.  J. 
Dairy Sci.  85:507–513.
Akers, R. M., D. E. Bauman, A. V. Capuco, G. T. Goodman, and H. 
A. Tucker. 1981a. Prolactin regulation of milk secretion and bio-
chemical differentiation of mammary epithelial cells in periparturi-
ent cows.  Endocrinology  109:23–30.
Journal of Dairy Science Vol. 95 No. 1, 2012
PROLACTIN INHIBITION AND MAMMARY FUNCTIONS 187
Akers, R. M., D. E. Bauman, G. T. Goodman, A. V. Capuco, and H. 
A. Tucker. 1981b. Prolactin regulation of cytological differentia-
tion of mammary epithelial cells in periparturient cows.  Endocri-
nology  109:31–40.
Andersen, C. L., J. L. Jensen, and T. F. Ørntoft. 2004. Normaliza-
tion of real-time quantitative reverse transcription-PCR data: A 
model-based variance estimation approach to identify genes suited 
for normalization, applied to bladder and colon cancer data sets. 
Cancer Res.  64:5245–5250.
Auchtung, T. L., A. G. Rius, P. E. Kendall, T. B. McFadden, and G. 
E. Dahl. 2005. Effects of photoperiod during the dry period on 
prolactin, prolactin receptor, and milk production of dairy cows. 
J. Dairy Sci.  88:121–127.
Baldi, A., S. Modina, F. Cheli, F. Gandolfi, L. Pinotti, L. B. Scesi, F. 
Fantuz, and V. Dell’Orto. 2002. Bovine somatotropin administra-
tion to dairy goats in late lactation: Effects on mammary gland 
function, composition and morphology.  J. Dairy Sci.  85:1093–
1102.
Ben Chedly, H., P. Lacasse, P.-G. Marnet, M. Komara, S. Marion, and 
M. Boutinaud. 2011. Use of milk epithelial cells to study regulation 
of cell activity and apoptosis during once-daily milking in goats. 
Animal  5:572–579.
Ben Chedly, H., P. Lacasse, P.-G. Marnet, S. Wiart-Letort, L. Finot, 
and M. Boutinaud. 2009. Cell junction disruption after 36h milk 
accumulation was associated with changes in mammary secretory 
tissue activity and dynamics in lactating dairy goats.  J. Physiol. 
Pharmacol.  60(Suppl. 3):105–111.
Berlanga, J. J., J. P. Garcia-Ruiz, M. Perrot-Applanat, P. A. Kelly, 
and M. Edery. 1997. The short form of the prolactin (PRL) recep-
tor silences PRL induction of the β-casein gene promoter.  Mol. 
Endocrinol.  11:1449–1457.
Bernier-Dodier, P., L. Delbecchi, G. F. Wagner, B. G. Talbot, and P. 
Lacasse. 2010. Effect of milking frequency on lactation persistency 
and mammary gland remodeling in mid-lactation cows.  J. Dairy 
Sci.  93:555–564.
Binart, N., A. Bachelot, and J. Bouilly. 2010. Impact of prolactin 
receptor isoforms on reproduction.  Trends Endocrinol. Metab. 
21:362–368.
Boutinaud, M., M. H. Ben Chedly, E. Delamaire, and J. Guinard-
Flament. 2008. Milking and feed restriction regulate transcripts 
of mammary epithelial cells purified from milk.  J. Dairy Sci. 
91:988–998.
Boutinaud, M., J. H. Shand, M. A. Park, K. Phillips, J. Beattie, D. J. 
Flint, and G. J. Allan. 2004. A quantitative RT-PCR study of the 
mRNA expression profile of the IGF axis during mammary gland 
development.  J. Mol. Endocrinol.  33:195–207.
Buck, K., M. Vanek, B. Groner, and R. K. Ball. 1992. Multiple forms 
of prolactin receptor messenger ribonucleic acid are specifically 
expressed and regulated in murine tissues and the mammary cell 
line HC11.  Endocrinology  130:1108–1114.
Capuco, A. V., S. E. Ellis, S. A. Hale, E. Long, R. A. Erdman, X. Zhao, 
and M. J. Paape. 2003. Lactation persistency: Insights from mam-
mary cell proliferation studies.  J. Anim. Sci.  81(Suppl. 3):18–31.
Choi, Y. J., W. L. Keller, I. E. Berg, C. S. Park, and A. G. Mackinlay. 
1988. Casein gene expression in bovine mammary gland.  J. Dairy 
Sci.  71:2898–2903.
Colitti, M., G. Stradaioli, and B. Stefanon. 2005. Mammary cell turn-
over in lactating ewes is modulated by changes of energy fuels. 
Res. Vet. Sci.  78:53–59.
Das, R., and B. K. Vonderhaar. 1995. Transduction of prolactin’s 
(PRL) growth signal through both long and short forms of the 
PRL receptor.  Mol. Endocrinol.  9:1750–1759.
Farr, V. C., K. Stelwagen, L. R. Cate, A. J. Molenaar, T. B. McFad-
den, and S. R. Davis. 1996. An improved method for the routine 
biopsy of bovine mammary tissue.  J. Dairy Sci.  79:543–549.
Fawcett, H. A. C., S. A. Baldwin, and D. J. Flint. 1992. Hormonal 
regulation of the glucose transporter GLUT I in the lactating rat 
mammary gland.  Biochem. Soc. Trans.  20:17S.
Kim, J. Y., Y. Mizoguchi, H. Yamaguchi, J. Enami, and S. Sakai. 
1997. Removal of milk by suckling acutely increases the prolactin 
receptor gene expression in the lactating mouse mammary gland. 
Mol. Cell. Endocrinol.  131:31–38.
Knight, C. H. 2000. Overview of prolactin’s role in farm animal lacta-
tion.  Livest. Prod. Sci.  70:87–93.
Knight, C. H., M. Peaker, and C. J. Wilde. 1998. Local control of 
mammary development and function.  Rev. Reprod.  3:104–112.
Knight, C. H., and C. J. Wilde. 1987. Mammary growth during lacta-
tion: Implications for increasing milk yield.  J. Dairy Sci.  70:1991–
2000.
Lacasse, P., V. Lollivier, R. M. Bruckmaier, Y. R. Boisclair, G. F. 
Wagner, and M. Boutinaud. 2011. Effect of the prolactin-release 
inhibitor quinagolide on lactating dairy cows.  J. Dairy Sci. 
94:1302–1309.
Lesueur, L., M. Edery, S. Ali, J. Paly, P. A. Kelly, and J. Djiane. 
1991. Comparison of long and short forms of the prolactin receptor 
on prolactin-induced milk protein gene transcription.  Proc. Natl. 
Acad. Sci. USA  88:824–828.
Littlejohn, M. D., C. G. Walker, H. E. Ward, K. B. Lehnert, R. G. 
Snell, G. A. Verkerk, R. J. Spelman, D. A. Clark, and S. R. Davis. 
2010. Effects of reduced frequency of milk removal on gene expres-
sion in the bovine mammary gland.  Physiol. Genomics  41:21–32.
Olazabal, I., J. Muñoz, S. Ogueta, E. Obregón, and J. P. García-
Ruiz. 2000. Prolactin (PRL)-PRL receptor system increases cell 
proliferation involving JNK (c-Jun amino terminal kinase) and 
AP-1 activation: Inhibition by glucocorticoids.  Mol. Endocrinol. 
14:564–575.
Perrot-Applanat, M., O. Gualillo, A. Pezet, V. Vincent, M. Edery, 
and P. A. Kelly. 1997. Dominant negative and cooperative effects 
of mutant forms of prolactin receptor.  Mol. Endocrinol.  11:1020–
1032.
Pfaffl, M. W., A. Tichopad, C. Prgomet, and T. P. Neuvians. 2004. 
Determination of stable housekeeping genes, differentially regu-
lated target genes and sample integrity: BestKeeper–Excel-based 
tool using pair-wise correlations.  Biotechnol. Lett.  26:509–515.
Plaut, K., D. E. Bauman, N. Agergaard, and R. M. Akers. 1987. Effect 
of exogenous prolactin administration on lactational performance 
of dairy cows.  Domest. Anim. Endocrinol.  4:279–290.
Skarda, J., E. Urbanova, L.-M. Houdebine, C. Delouis, and J. Bilek. 
1982. Effects of insulin, cortisol and prolactin on lipid, protein 
and casein syntheses in goat mammary tissue in organ culture. 
Reprod. Nutr. Dev.  22:379–386.
Taylor, J. C., and M. Peaker. 1975. Effects of bromocriptine on milk 
secretion in the rabbit.  J. Endocrinol.  67:313–314.
Travers, M. T., M. C. Barber, E. Tonner, L. Quarrie, C. J. Wilde, 
and D. J. Flint. 1996. The role of prolactin and growth hormone 
in the regulation of casein gene expression and mammary cell sur-
vival: Relationships to milk synthesis and secretion.  Endocrinol-
ogy  137:1530–1539.
Wall, E. H., H. M. Crawford, S. E. Ellis, G. E. Dahl, and T. B. Mc-
Fadden. 2006. Mammary response to exogenous prolactin or fre-
quent milking during early lactation in dairy cows.  J. Dairy Sci. 
89:4640–4648.
Yu, C. C., and M. I. Filipe. 1993. Update on proliferation-associated 
antibodies applicable to formalin-fixed paraffin-embedded tissue 
and their clinical applications.  Histochem. J.  25:843–853.
